Personal Account
She Was A Biology Teacher. She Tested Everything. Then She Found The Real Problem.
And every well-sourced, mechanism-checked supplement she tried addressed the sensation. Not one of them touched what was keeping it on.
I kept a list.
I am a retired biology teacher. I kept a list.
Not out of some compulsion. Out of professional habit. When you have spent thirty-seven years telling sixteen-year-olds to document their observations before drawing conclusions, you do not skip that step when the problem is your own body. The list had a column for the supplement, a column for the dose, a column for the duration, and a column for the result.
The column for results was the same for fifteen items. It said: sensation addressed. Not the cause.
I should have seen that earlier. I had been filling in the results column carefully, accurately, and without noticing that every single entry was answering the wrong question.
The compound that finally did isn’t one most supplement buyers know about.
What fifteen items on a list tell you
The list started in the third year of the burning.
The first year I tried what most people try first: I called my GP and described what was happening. She ordered a B12 panel. The results were normal. She suggested a referral to neurology if it continued, and it continued, and I saw a neurologist who told me the nerve conduction study showed mild peripheral sensitivity.
“Consistent with age.”
She said it the way people say things that are true but not useful. I wrote it down. I added a column to the list: what the professional recommended. That column eventually had four entries. None of them led anywhere I hadn’t already been.
Fifteen items. Each one entered in the results column. None of them answered the question I eventually learned to ask.
The failure catalogue, in approximate chronological order.
Alpha-lipoic acid. $34 for sixty capsules. I took it for eight weeks. The burning diminished slightly at week four. By week six it was back to baseline. I kept it in the results column: minor transient reduction.
Magnesium glycinate. $28. Eight weeks. Sleep improved marginally in weeks two and three. By week seven, no meaningful change in the burning. Results column: sleep improvement, burning unchanged.
Methylcobalamin B12 sublinguals. $22. Three months. No measurable change. Results column: nothing.
Benfotiamine. $52. The review that sold me on this one was from a woman on Amazon who said it had “basically eliminated” her nerve pain. Changed my life. The nerve pain is basically gone. That was the sentence that made me order it. Forty-three days later I had used the full bottle and the burning was unchanged. I entered the result in the column and noted the discrepancy between what she had written and what I observed.
CBD topical. $78. Six weeks. Local cooling sensation lasting thirty to forty minutes. No change in nighttime burning.
Cooling spray. $19. Thirty to forty-five minutes of relief. I used it for eleven months.
By the end of year three the list had fifteen items and the results column said the same thing for all of them. The supplement with the highest-rated mechanism on paper gave me the most carefully justified version of nothing.
The folded towel was on the results list too. Mechanism: contact avoidance. Duration: indefinite.
The question I hadn’t asked
In the third year of the burning, I filled in the mechanism-target column for all fifteen items on the list.
It was a Thursday evening in late autumn. I had been sitting at the kitchen table for two hours with a legal pad and my laptop. What I was trying to do was identify whether any of the fifteen things I had tried were aimed at the cellular mechanism responsible for the burning — not the sensation of the burning, but the mechanism driving it.
The answer was the same for all fifteen.
That Thursday I spent $62 on journal access and ordered a PubMed search of palmitoylethanolamide and peripheral neuropathy. I found the Lang-Illievich 2023 meta-analysis. I read the full paper that night. I read two more papers over the following two weeks. I ordered one bottle, skeptically, with my thirty-seventh-year biology-teacher instinct active: don’t draw conclusions from one trial.
Thursday evening. The mechanism-target column. Every item aimed at the sensation. Not one aimed at the cause.
The mechanism, when I read it, was the kind of finding that makes you stop and re-read the paragraph.
Your body produces a compound called palmitoylethanolamide — PEA — on demand, in response to nerve stress and inflammation. It activates a receptor called PPAR-alpha inside overactive mast cells and glial cells, which are the immune cells in close contact with your nerves. When that receptor is activated, the cells’ inflammatory output drops. The nerve signal quiets.
Under normal circumstances, that system runs continuously and you never notice it. Under chronic irritation — the kind that has been running for months or years — the demand for PEA eventually exceeds what the body can produce on demand. The supply runs low. The brake on the nerve signal gets thin.
The compound is not patented. That is the complete explanation for why my GP had never mentioned it.
I had been wrong before about mechanism-based reasoning. The benfotiamine review had not matched the result I experienced. The Amazon reviewer had written “basically eliminated.” I had written “unchanged” in my column.
The difference between the benfotiamine and the PEA is that the PEA mechanism is documented in controlled clinical trials. The benfotiamine reviewer may have had a B1 deficiency. I probably didn’t. With PEA I had a mechanism and I had trial data.
I ordered one bottle. I did not update the results column immediately.
I had treated the sensation of a system running short of its own calming mechanism. For three years.
The formula I eventually put on the list: youfirstlab.com/products/pea600 →
Why the flame gets smaller without going out
The candle analogy is the one that made the mechanism clear to me.
A candle produces light the way your body produces PEA — steadily, on demand, from a reserve that replenishes itself under normal conditions. Under normal conditions you don’t notice the reserve. You notice the light. Under extended burn — the kind of chronic inflammatory stress that peripheral nerve pain represents — the reserve drops below the level where the output keeps pace. The flame doesn’t go out. It gets smaller. The calming mechanism doesn’t stop. It gets insufficient.
The flame doesn’t go out. It runs low. The calming mechanism doesn’t stop — it gets insufficient.
That was not the mechanism any of the fifteen items on my list had addressed. Not one of them. I had been filling in the results column for three years and the column was answering the wrong question.
What the category was built around
The category I had been shopping in for three years was not built around that mechanism.
It was built around the sensation. Cooling the skin. Blocking the signal. Supporting general nerve metabolism. Every product on the shelf offered something that would address what you felt — for an interval. None of them addressed what was causing you to feel it.
I do not think this was fraud. I think it was the natural result of a commercial structure that rewards labeling a compound as “nerve support” without any requirement to specify which aspect of nerve function it supports. The label is accurate. It is not informative.
The woman on Amazon who wrote that benfotiamine had “basically eliminated” her nerve pain was probably not lying. She may have had a deficiency I didn’t. She responded. I didn’t. The results column is for what happens to you, not for what happens to the most vocal person who tried it before you.
The supplement with the highest-rated mechanism on paper gave me the most carefully justified version of nothing.
Day four. Something changed.
I didn’t expect to notice anything before week three.
That turned out to be wrong.
I did not rearrange my feet until 1:27am. I checked the clock because I noticed I had not checked the clock. That was a data point. I wrote it in the results column with a question mark.
I slept until 3:45am. The entry in the results column for that night reads: “Slept to 0345. Burning not primary waking cause. Query: second consecutive event or coincidence. Continue observation.”
I put on the thick socks. Not the thin ones I reserved for manageable nights. The first pair I took out of the drawer. I was halfway down the stairs before I noticed I hadn’t calculated whether I could.
I was working on a crossword at the kitchen table with a cup of coffee. My sister Ruth called. We talked for forty minutes. When I hung up the phone she said: “You seemed like yourself today.”
I did not tell her what I had been taking. I wrote her comment down instead.
Week five. She said: “You seemed like yourself today.” I wrote it down.
PEA at the clinical dose is the one I’d put on a different list. The product is at youfirstlab.com/products/pea600.
See the Formula I Chose A 90-day money-back guarantee applies. My recommendation: the three-bottle configuration — the minimum reasonable window to assess a compounding mechanism.What better means, specifically
A note on what better means, specifically.
Better is not the same as gone. The burning has not disappeared. On nights when I am more active or when the weather is extreme, I notice it. What has changed is the baseline and the ceiling. The baseline is no longer “burning that disrupts sleep consistently.” The ceiling is no longer “nights where I cannot tolerate any covering.”
I have been taking Youfirst PainBloc PEA 600MG since the sixteenth entry on the list. I am still taking it. If I stop for two weeks the baseline begins to shift. That tells me the mechanism is active — which is what I would expect from a system that has been running on insufficient supply for years. It does not fully self-repair in the absence of the compound. The compound is the maintenance input now.
Subscription pricing: $29.99 for one bottle, $59.99 for two bottles with a third included. One-time pricing: $39.99 for one bottle, $79.99 for two bottles with a third included. There is a 90-day money-back guarantee.
My recommendation: the three-bottle configuration. A 90-day trial is the minimum reasonable window to assess a compounding mechanism. That is what the guarantee covers.
P.S. — The results column for item sixteen currently has the most data points of any entry on the list. It is the only item I have reordered.
I still have the list.